Evidence map›Paper›PMID 39125541›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Utility and Micro-Costing Framework for

Leire Barrutia, Ed Schuuring, Emõke Rácz, Gilles F H Diercks, Léon C van Kempen

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Leire BarrutiaDepartment of Pathology and Medical Biology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-7174-411X
Ed SchuuringDepartment of Pathology and Medical Biology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-3655-143X
Emõke RáczDepartment of Dermatology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Gilles F H DiercksDepartment of Pathology and Medical Biology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Léon C van KempenDepartment of Pathology and Medical Biology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-0646-0705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2018 WHO edition on the classification of cutaneous melanocytic tumors recognizes eight evolutionary pathways of melanoma and describes tumors of uncertain malignant potential for each. When histology and immunohistochemistry do not support a confident conclusion about its malignant potential, a window of diagnostic uncertainty is created. Mutations in the telomerase reverse transcriptase gene promoter (

Indexed as

melanocytic tumorsmicro-costing frameworkTERT

Identifiers

PMID39125541
PMCPMC11311256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.